Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · Real-Time Price · USD
1.060
0.00 (0.00%)
At close: Mar 9, 2026, 4:00 PM EDT
0.998
-0.062 (-5.84%)
After-hours: Mar 9, 2026, 4:23 PM EDT
Company Description
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments.
The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer.
It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies.
Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Oncolytics Biotech Inc.
| Country | Canada |
| Founded | 1998 |
| IPO Date | Nov 8, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Jared Kelly |
Contact Details
Address: 322 11th Avenue SW, Suite 804 Calgary, AB T2R 0C5 Canada | |
| Phone | 403 670 7377 |
| Website | oncolyticsbiotech.com |
Stock Details
| Ticker Symbol | ONCY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| CIK Code | 0001129928 |
| CUSIP Number | 682310875 |
| ISIN Number | CA6823108759 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jared Kelly J.D., L.L.M. | Chief Executive Officer and Director |
| Kirk J. Look C.A., CPA | Chief Financial Officer |
| Allison Hagerman P.Eng., P.M.P. | Chief Technology Officer |
| Dr. Thomas C. Heineman M.D., Ph.D. | Chief Medical Officer |
| John McAdory | Executive Vice President of Strategy and Operations |
| Jon Patton | Director of Investor Relations and Communication |
| Andrew P. Aromando | Chief Business Officer |
| Yujun Wu | Vice President and Head of Biostatistics |
| John Mark Lievonen B.B.A., CM, F.C.A., FCPA, LLD, M.B.A. | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 2, 2026 | 8-K | Current Report |
| Feb 24, 2026 | 8-K | Current Report |
| Feb 4, 2026 | 8-K | Current Report |
| Jan 15, 2026 | 8-K | Current Report |
| Jan 15, 2026 | 8-K | Current Report |
| Jan 12, 2026 | 8-K | Current Report |
| Jan 9, 2026 | 425 | Filing |
| Jan 7, 2026 | 6-K | Report of foreign issuer |
| Dec 16, 2025 | 6-K | Report of foreign issuer |
| Dec 10, 2025 | 6-K | Report of foreign issuer |